Page last updated: 2024-11-12

thiostrepton

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Thiostrepton: One of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria. In veterinary medicine, it has been used in mastitis caused by gram-negative organisms and in dermatologic disorders. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

thiostrepton : A heterodetic cyclic peptide, in which the cyclisation step involves a formal lactonisation between the carboxy group of a quinaldic acid-based residue and a secondary alcohol. An antibiotic that inhibits bacterial protein synthesis. Also acts as an antitumor agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID23760132
CHEMBL ID4303577
MeSH IDM0021380

Synonyms (11)

Synonym
BPBIO1_000555
PRESTWICK3_000522
AB00513852
thiostrepton
HMS2096J05
thiostrepton from streptomyces azureus
AKOS025310682
CCG-220522
HMS3713J05
alaninamide;bryamycin;thiactin
CHEMBL4303577

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" These data suggest that this drug combination may be useful as a therapy for solid tumors."( Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton.
Gartel, AL; Wang, M, 2012
)
0.38
" In this study, we examined the effects of FoxM1 inhibitor Thiostrepton (THIO) alone or in combination with MEK inhibitor Selumetinib (SEL) on metastatic parameters in vitro and in vivo."( Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis.
Demirtas Korkmaz, F; Dogan Turacli, I; Ekmekci, A; Esendagli, G, 2022
)
0.72
" THIO was more effective than in combination with SEL in terms of metastatic protein expressions in vivo."( Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis.
Demirtas Korkmaz, F; Dogan Turacli, I; Ekmekci, A; Esendagli, G, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Furthermore, the in vivo production of variants can be employed to interrogate thiopeptide structure-activity relationships and may be useful to address the bioavailability issues plaguing these otherwise promising lead molecules."( In vivo production of thiopeptide variants.
Kelly, WL; Zhang, F, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (348)

TimeframeStudies, This Drug (%)All Drugs %
pre-199070 (20.11)18.7374
1990's61 (17.53)18.2507
2000's67 (19.25)29.6817
2010's118 (33.91)24.3611
2020's32 (9.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.28%)5.53%
Reviews7 (1.98%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other345 (97.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Translational Phase 1/2 Dose-Escalation and Expansion Study to Determine Safety, Tolerability, and Recommended Phase 2 Dose of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma [NCT05278975]Phase 1/Phase 2186 participants (Anticipated)Interventional2022-03-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]